Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-09-09
2008-08-19
McGarry, Sean (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
07414034
ABSTRACT:
The present invention relates to a method of treatment of Parkinson's disease, and to the use of antisense oligonucleotides or triplex oligonucleotides introduced into targeted brain structures to decrease the function of brain circuits known to be overactive in the Parkinsonian brain. Antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata (SNr) where the expression of glutamic acid decarboxylase (GAD67, GAD65, or a combination of the two isoforms) is downregulated. The present invention also relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the internal globus pallidus and/or substantia nigra pars reticulata for the downregulation of glutamate receptors. The present invention further relates to a method of treatment of Parkinson's disease where antisense or triplex oligonucleotides are targeted to the thalamic motor nuclei for the downregulation of GABA receptors.
REFERENCES:
patent: 5929042 (1999-07-01), Troy et al.
patent: 5929226 (1999-07-01), Padmapriya et al.
Braasch et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry, 2002 vol. 41:4503-4510.
Tamm, I. et al. Antisense therapy in oncology: new hope for an old idea. The Lancet. Aug. 2001, 358: 489-497.
Ma et al.,Biotechnology Annual Review, vol. 5, 2000, pp. 155-196.
Jen at al.,Stem Cells, vol. 18, 2000, pp. 307-319.
Green et al.,J. Am. Coll. Surg., vol. 191, No. 1, Jul. 2000, pp. 93-105.
Agrawal et al.,Molecular Medicine Today, vol. 6, Feb. 2000, pp. 72-81.
Bennett et al.,Chapter 2 from Methods in Molecular Medicine: Antisense Therapeutics(Ed. Agrawal), Humana. Press Inc. Totowa, N.J., 1996, pp. 13-46.
Branch,TIBS23, pp. 45-50, Feb. 1998.
Flanagan et al.,Nature Biotechnology, vol. 17, No. 1, pp. 48-52, Jan. 1999.
McCarthy, M.M. et al., “Intracerebral administration of antisense oligodeoxynucleotides to GAD 65 and GAD 67 mRNAs modulate reproductive behavior in the famale rat”,Brain Research, 1994, 636, 209-220.
Mitsushima, D. et al., “Role of glutamic acid decarboxylase in the prepubertal inhibition of the luteinizing hormone releasing hormone release in female rhesus monkeys”,The Journal of Neuroscience, 1996, 16(8), 2563-2573.
Stull, R.A. et al., “Predicting Antisense Oligonucleotide Inhibitory Efficacy: A Computational Approach Using Histograms and Thermodynamic Indices”,Nucleic Acids Research, vol. 20, No. 13, pp. 3501-3508, 1992.
Stull, R.A., et al., “An in vitro Messenger RNA Binding Assay as a Tool for Identifying Hybridization-competent Antisense Oligonucleotides”,Antisense&Nucleic Acid Drug Development, vol. 6, pp. 221-228, 1996.
Bacon, Thomas A. and Wickstrom, E., “Walking Along Human c-mycmRNA with Antisense Oligodeoxynucleotides: Maximum Efficacy at the 5′ Cap Region”,Oncogene Research, vol. 6., pp. 13-19, 1991.
Bennett, C.F. et al., “Pharmacology of Antisense Therapeutic Agents”,Methods in Molecular Medicine: Antisense Therapeutics(Agrawal, S., ed.), Humana Press, Totowa, New Jersey, pp. 13-46, 1996.
Akhtar, S. and Agrawal, S., “In vivo Studies with Antisense Oligonucleotides”,Trends in Pharmacol. Sciences, vol. 18, pp. 12-18, 1997.
Brysch, et al., “Antisense-Mediated Inhibition of Protein Synthesis”,Methods in Molecular Medicine: Antisense Therapeutics, (Agrawal, S., ed.), Humana Press, Totowa, New Jersey, pp. 166 and 175-176, 1996.
Cossum, P.A. et al., “Disposition of the C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intravenous Administration to Rats”,J. Pharmacol. Exp. Ther., vol. 267, No. 3, pp. 1181-1190, 1993.
Cossum, P.A., et al., “Pharmacokinetics of a C-Labeled Phosphorothioate Oligonucleotide, ISIS 2105, after Intradermal Administration to Rats”,J. Pharmacol. Exp. Ther., vol. 269, No. 1, pp. 89-94, 1994.
Agrawal, S., et al., “Pharmacokinetics, Biodistribution, and Stability of Oligodeoxynucleotide Phophorothioates in Mice”,Proc. Natl. Acad. Sci., vol. 88, pp. 7595-7599, 1991.
Temsamani, J., et al., “Pharmacokinetics, Biodistribution , and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice”,Antisense Res. Dev., vol. 3: 277-284, 1993.
Sands, H., et al., “Biodistribution and Metabolism of Internally H-Labeled Oligonucleotides. I. Comparison of a Phosphodiester and a Phosphorothioate”,Mol. Pharmacol., vol. 45, pp. 932-943, 1994.
Saijo, Y., et al., “Pharmacokinetics, Tissue Distribution , and Stability of Antisense Oligodeoxynucleotide Phosphorothiate ISIS 3466 in Mice”,Oncol. Res., vol. 6:243-249, 1994.
DeDiesbach, P., et al., “Identification, Purification and Partial Characterization of an Oligonucleotide Receptor in Membranes of HepG2 Cells”, Nucleic Acids Res Feb. 15, 2000;28(4):868-74.
Loke, S.L., et al., “Characterization of Oligonucleotide Transport into Living Cells”,Proc. Natl. Acad. Sci. USA, vol. 86, pp. 3474-3478, May 1989.
Hanss, B., et al., “Identification and Characterization of a Cell Membrane Nucleic Acid Channel”,Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1921-1926, Feb. 1998.
Benimetskaya, L. et al., “Mac-1 (CD11b/CD18) is an Oligodeoxynucleotide-binding Protein”,Nature Medicine, vol. 3, No. 4, pp. 414-420, 1997.
Yakubov, Leonid A., et al., “Mechanism of Oligonucleotide Uptake by Cells: Involvement of Specific Receptors?”,Proc. Natl. Acad. Sci. USA vol. 86:6454-6458, Sep. 1989.
Politz, Joan C., et al., “Intranuclear Diffusion and Hybridization State of Oligonucleotides Measured by Fluorescence Correlation Spectroscopy in Living Cells”,Proc. Natl. Acad. Sci., USA, vol. 95, pp. 6043-6048, May 1998.
Politz, Joan C., et al., “Characterization of Hybridization Between Synthetic Oligodeoxynucleotides and RNA in Living Cells”,Nucleic Acids Research, vol. 23, No. 24, 1995.
Whitesell, Luke, et al., “Stability, Clearance, and Disposition of Intraventricularly Administered Oligodeoxynucleotides: Implications for Therapeutic Application Within the Central Nervous System”,Proc. Natl. Acad. Sci., USA, vol. 90:4665-4669, May 1993.
International Search Report mailed Feb. 22, 2000 from corresponding International Application No. PCT/US99/26128, filed Nov. 5, 1999.
Gibbs Terra Cotta
McGarry Sean
Pepper Hamilton LLP
Thomas Jefferson University
LandOfFree
Treatment of Parkinson's disease with oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of Parkinson's disease with oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Parkinson's disease with oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002168